Rare Disease Pipeline

An Unwavering Commitment to Patients and Ethical Research

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with rare disease. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages. Search here to learn more about clinical trials in your area and for the investigational therapies in which you are most interested.

Rare Disease Pipeline & Trials

Rare Disease Pipeline as of August 1, 2017

Download Complete Pipeline PDF

Discovery Projects
Phase 1

5
Phase 2

2
Phase 3

4
Registration

1
Total12

Compound Name	Indication	Phase	Submission Type	Compound Type
PF-04447943 Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRD Mechanism of Action: PDE9 Inhibitor Go to clinical trial	Sickle Cell Anemia (ORPHAN - U.S.)	Phase 1	New Molecular Entity	Small Molecule
PF-05230907 Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Biologic Business Segment: WRD Mechanism of Action: Factor Xa Protein Replacement Go to clinical trial	Intracerebral Hemorrhage (Biologic) (ORPHAN - U.S.)	Phase 1	New Molecular Entity	Biologic
PF-06730512 Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Biologic Business Segment: WRD Mechanism of Action: Antagonist Go to clinical trial	Nephrotic Syndrome (Biologic) Project advanced	Phase 1	New Molecular Entity	Biologic
PF-06741086 Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Biologic Business Segment: WRD Mechanism of Action: Tissue Factor Pathway Inhibitor (TFPI) Go to clinical trial	Hemophilia (Biologic) (ORPHAN - U.S., E.U.)	Phase 1	New Molecular Entity	Biologic
PF-06838435 Therapeutic Area: Rare Diseases Phase:Phase 2 Compound Type:Biologic Business Segment: WRD Mechanism of Action: Gene Therapy, coagulation factor IX (F9) Go to clinical trial	Hemophilia (Biologic) (BREAKTHROUGH, ORPHAN - U.S., PRIME - E.U.)	Phase 2	New Molecular Entity	Biologic
PF-07055480 (SB-525) Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Biologic Business Segment: WRD Mechanism of Action: AAV-FVIII GTx Go to clinical trial	Hemophilia (Biologic) (ORPHAN - U.S., E.U.) Project advanced	Phase 1	New Molecular Entity	Biologic
Vyndaqel (tafamidis meglumine) Therapeutic Area: Rare Diseases Phase:Phase 3 Compound Type:Small Molecule Business Segment: Pfizer Innovative Health Mechanism of Action: Transthyretin (TTR) Dissociation Inhibitor Go to clinical trial	Adult Symptomatic Transthyretin Cardiomyopathy (FAST TRACK, ORPHAN - U.S., E.U. **)	Phase 3	Product Enhancement	Small Molecule
domagrozumab (PF-06252616) Therapeutic Area: Rare Diseases Phase:Phase 2 Compound Type:Biologic Business Segment: WRD Mechanism of Action: Myostatin Inhibitor Go to clinical trial	Duchenne Muscular Dystrophy (Biologic) (FAST TRACK, ORPHAN - U.S., E.U.)	Phase 2	New Molecular Entity	Biologic
rivipansel (GMI-1070) Therapeutic Area: Rare Diseases Phase:Phase 3 Compound Type:Small Molecule Business Segment: Pfizer Innovative Health Mechanism of Action: Pan-Selectin Antagonist Go to clinical trial	Vaso-occlusive crisis associated with Sickle Cell Disease (FAST TRACK, ORPHAN - U.S., E.U.)	Phase 3	New Molecular Entity	Small Molecule
somatrogon (PF-06836922) Therapeutic Area: Rare Diseases Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Human Growth Hormone Agonist Go to clinical trial	Pediatric Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) Project advanced	Phase 3	Product Enhancement	Biologic
somatrogon (PF-06836922) Therapeutic Area: Rare Diseases Phase:Phase 3 Compound Type:Biologic Business Segment: Pfizer Innovative Health Mechanism of Action: Human Growth Hormone Agonist Go to clinical trial	Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.)	Phase 3	New Molecular Entity	Biologic
tafamidis meglumine Therapeutic Area: Rare Diseases Phase:Registration Compound Type:Small Molecule Business Segment: Pfizer Innovative Health Mechanism of Action: Transthyretin (TTR) Dissociation Inhibitor Go to clinical trial	Transthyretin familial amyloid polyneuropathy (U.S.) (FAST TRACK, ORPHAN - U.S.)	Registration	New Molecular Entity	Small Molecule